Cost-Effectiveness of Medicinal Cannabis for Management of Refractory Symptoms Associated With Chronic Conditions: A Systematic Review of Economic Evaluations

Erku, Daniel Asfaw; Shrestha, Shakti; Scuffham, Paul Anthony

doi:10.1016/j.jval.2021.04.1276

Cited by 5 publications

(2 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Some examples here might include the reduction of the use of biologics and monoclonal antibodies in autoimmune diseases like rheumatoid or Crohn’s disease, whereby CBMPs would likely be cheaper in this instance. In order to assess the cost effectiveness of CBMPs for various conditions, health economic analyses are required ( 5 ).…”

Section: Introduction: Medical Cannabis In the United Kingdommentioning

confidence: 99%

The value of real world evidence: The case of medical cannabis

Schlag

Zafar

Lynskey³

et al. 2022

Front. Psychiatry

View full text Add to dashboard Cite

Randomised controlled trials (RCTs) have long been considered the gold standard of medical evidence. In relation to cannabis based medicinal products (CBMPs), this focus on RCTs has led to very restrictive guidelines in the UK, which are limiting patient access. There is general agreement that RCT evidence in relation to CBPMs is insufficient at present. As well as commercial reasons, a major problem is that RCTs do not lend themselves well to the study of whole plant medicines. One solution to this challenge is the use of real world evidence (RWE) with patient reported outcomes (PROs) to widen the evidence base. Such data increasingly highlights the positive impact medical cannabis can have on patients’ lives. This paper outlines the value of this approach which involves the study of interventions and patients longitudinally under medical care. In relation to CBMPs, RWE has a broad range of advantages. These include the study of larger groups of patients, the use of a broader range and ratio of components of CBMPs, and the inclusion of more and rarer medical conditions. Importantly, and in contrast to RCTs, patients with significant comorbidities–and from a wider demographic profile–can also be studied, so providing higher ecological validity and increasing patient numbers, whilst offering significant cost savings. We conclude by outlining 12 key recommendations of the value of RWE in relation to medical cannabis. We hope that this paper will help policymakers and prescribers understand the importance of RWE in relation to medical cannabis and help them develop approaches to overcome the current situation which is detrimental to patients.

show abstract

Section: Introduction: Medical Cannabis In the United Kingdommentioning

confidence: 99%

The value of real world evidence: The case of medical cannabis

Schlag

Zafar

Lynskey³

et al. 2022

Front. Psychiatry

View full text Add to dashboard Cite

show abstract

“…No contexto do tratamento da dor crônica, o uso de canabinóides parece apresentar benefícios, entretanto, não há consenso sobre a eficácia, dose ideal, tempo de uso e seus efeitos adversos a longo prazo, temáticas ainda não completamente compreendidas 13 . Em uma análise recente de custo-benefício, o uso de nabiximol foi recomendado para o controle da espasticidade em pacientes com esclerose múltipla, algumas síndromes convulsivas infantis e dor crônica, mas essas conclusões podem ser significativamente modificadas de acordo com a prática clínica e as características do sistema de saúde 13,21 .…”

Section: Discussionunclassified

O impacto do canabidiol nos distúrbios neuromotores: relato de caso e revisão da literatura

Da Silva,

E Silva,

Walker

et al. 2024

Braz. J. Hea. Rev.

View full text Add to dashboard Cite

Objetivo: O atual estudo objetiva relatar e discutir os benefícios do uso de canabinoídes em paciente do sexo masculino com sequelas neuromotoras decorrente de processo hipoxêmico prolongado. Método: Fez-se um compilado de dados presentes em prontuários médicos, exames complementares e do acompanhamento médico do paciente em regime de Home Care, bem como complementação teórica mediante revisão narrativa da literatura, por meio de busca ativa de publicações, entre 2018 e 2023, nas bases de dados eletrônicas Scielo e PubMed, utilizando os descritores “Canabidiol”, “Adaptação Psicológica”, “Qualidade de Vida” e “Neuropatia”, incluídos, por fim, 22 artigos. Resultados: No caso descrito, observou-se uma diminuição do limiar de dor, maior grau de interação social e melhora da espasticidade, do apetite e do padrão de sono, contribuindo para a desprescrição de medicações de uso contínuo e, consequentemente, na redução de eventos adversos farmacológicos. Conclusões: Reforça-se a importância da busca por terapias adjuvantes com o melhor custo benefício e menor efeitos deletério para o tratamento da sintomatologia crônica dos distúrbios neuromotores. Assim, o uso dos derivados da cannabis, com destaque para o canabidiol, pode ter papel de contribuição para a melhora da qualidade de vida de pacientes com sequelas neuromotoras.

show abstract

Medicinal cannabis may be cost effective for alleviating refractory symptoms associated with chronic conditions

2021

PharmacoEcon Outcomes News

View full text Add to dashboard Cite

Cost-Effectiveness of Medicinal Cannabis for Management of Refractory Symptoms Associated With Chronic Conditions: A Systematic Review of Economic Evaluations

Cited by 5 publications

References 23 publications

The value of real world evidence: The case of medical cannabis

The value of real world evidence: The case of medical cannabis

O impacto do canabidiol nos distúrbios neuromotores: relato de caso e revisão da literatura

Medicinal cannabis may be cost effective for alleviating refractory symptoms associated with chronic conditions

Contact Info

Product

Resources

About